Vivek Subbiah: Such a delight to share our non-human primate publication as a pre-cursor to our First-in-human phase 1 trial

Vivek Subbiah shared on X/Twitter:

”Such a delight to share our non-human primate publication on First-in-cynomolgus macaques study as a pre-cursor to our First-in-human phase 1 trial. Dosimetry of a Novel 111 Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates. Thrilled to collaborate with a diverse and talented team of veterinary doctors and nuclear medicine experts for this special work that enabled the design of the human Phase 1 trial.

Link to non-human primate work via Cancers MDPI.

Link to Phase 1 trial in AACR journal Clinical Cancer Research.

Dosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates mdpi cancers via Cancers MDPI. For the article click here.

Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors Clinical Cancer Research, AACR. For the article click here.”

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.